G1 Therapeutics (GTHX)
(Delayed Data from NSDQ)
$7.15 USD
+0.02 (0.28%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $7.15 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth D Momentum C VGM
Income Statements
Fiscal Year end for G1 Therapeutics falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 83 | 51 | 31 | 45 | 0 |
Cost Of Goods | 7 | 4 | 2 | 0 | 0 |
Gross Profit | 75 | 48 | 29 | 45 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 115 | 184 | 172 | 142 | 129 |
Income After Depreciation & Amortization | -40 | -136 | -142 | -96 | -129 |
Non-Operating Income | 5 | 1 | 0 | 0 | 7 |
Interest Expense | 10 | 10 | 5 | 2 | 0 |
Pretax Income | -45 | -146 | -147 | -98 | -122 |
Income Taxes | 3 | 2 | 1 | 1 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -48 | -148 | -148 | -99 | -122 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -48 | -148 | -148 | -99 | -122 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -38 | -133 | -141 | -95 | -129 |
Depreciation & Amortization (Cash Flow) | 2 | 3 | 2 | 1 | 0 |
Income After Depreciation & Amortization | -40 | -136 | -142 | -96 | -129 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 51.73 | 43.63 | 41.94 | 37.88 | 37.50 |
Diluted EPS Before Non-Recurring Items | -0.93 | -3.38 | -3.54 | -2.62 | -3.27 |
Diluted Net EPS (GAAP) | -0.93 | -3.38 | -3.54 | -2.62 | -3.27 |
Fiscal Year end for G1 Therapeutics falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 16.55 | 14.48 | 14.87 | 12.30 | 42.39 |
Cost Of Goods | 0.73 | 1.08 | 1.26 | 3.08 | 1.40 |
Gross Profit | 15.81 | 13.40 | 13.62 | 9.22 | 40.99 |
SG&A, R&D, and Dept/Amort Expenses | 19.35 | 22.45 | 22.55 | 25.59 | 29.47 |
Income After SG&A, R&D, and Dept/Amort Expenses | -3.54 | -9.05 | -8.93 | -16.37 | 11.52 |
Non-Operating Income | 0.79 | 0.81 | 2.25 | 1.18 | 1.21 |
Interest Expense | 2.73 | 1.98 | 2.12 | 2.12 | 2.71 |
Pretax Income | -5.47 | -10.22 | -9.98 | -17.30 | 10.02 |
Income Taxes | 0.00 | 0.00 | 0.90 | 0.91 | 1.31 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -5.47 | -10.22 | -10.88 | -18.20 | 8.71 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -5.47 | -10.22 | -10.88 | -18.20 | 8.71 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 52.48 | 52.17 | 51.84 | 51.78 | 61.04 |
Diluted EPS Before Non-Recurring Items | -0.10 | -0.20 | -0.21 | -0.35 | 0.14 |
Diluted Net EPS (GAAP) | -0.10 | -0.20 | -0.19 | -0.35 | 0.14 |